BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target

BTIG analyst Jeet Mukherjee has reiterated a Buy rating on Innate Pharma (NASDAQ: IPHA) while maintaining a price target of $9. This endorsement suggests confidence in the company's future performance in the market.